Abstract Book of the ESMO Immuno-Oncology Congress 2024, 11-13 December 2024Publication of this Abstract book is supported by the European Society for Medical Oncology December 2024 Previous vol/issue Next vol/issue Actions for selected articles ...
home / conference / esmo-immuno-oncology-congress Content TypeBMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy By Chris Ryan January 4th 2025 BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced ...
A restricted number of ESMO Merit Travel Grants to the the ESMO Immuno-Oncology Congress 2024 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must beESMO Members under the age of 40. Selection will be made...
A restricted number of ESMO Merit Travel Grants to the the ESMO Immuno-Oncology Congress 2024 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must beESMO Members under the age of 40. Selection will be made...
today announced that it will display three poster presentations on 23ME-00610, a first-in-class anti-CD200R1 antibody, and two on 23ME-01473, an anti-ULBP6 monoclonal antibody, at the European Society for Medical Oncology (ESMO) Congress 2024, taking place September...
Poster presentation 12th Dec at 12:15 Documents ESMO_final 2.0 Geneva, CHAdd to Calendar May 28 - May 29, 2025 Circular & Self-Amplifying RNA Therapeutics Summit Boston, USAAdd to Calendar June 5, 2025 Annual General Meeting 2025 Add to Calendar ...
ESMO-IO 欧洲肿瘤内科学会 免疫肿瘤学大会ESMO Immuno-Oncology Congress ESCC 食管鳞状细胞癌Esophageal Squamous Cell Carcinoma FL 滤泡性淋巴瘤 Follicular Lymphoma FTC 输卵管癌Fallopian Tube Cancer GC 胃癌 Gastric Cancer GMP Good Manufacturing Practice《药品生产质量管理规范》 ...
drug candidates fruquintinib, surufatinib and HMPL-295, which will be presented at the upcomingEuropean Society for Medical Oncology(“ESMO”)Asia Congress, taking place onDecember 1-3, 2023inSingapore, and theESMO Immuno-Oncology Congress, taking place onDecember 6-8, 2023inGe...
Henlius has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first Chin...
data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with axitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) were presented at the European Society for Medical Oncology Immuno-Oncology Congress 2024 (ESMO IO Congress 2024)....